SEC-sourced researchBeta

WST

WEST PHARMACEUTICAL SERVICES INC

US markets

Data passport

CIK: 0000105770
Exchange: NYSE
Business activity: — · SIC 3841
Financial inputs: 6/6
Filing date: Oct 2, 2026
SEC registry record: Operating company

Last updated: Oct 8, 2026, 11:04 AM UTCSEC company ticker catalog ↗SEC Financial Statement Data Sets ↗SEC investment company series and class registry ↗

Annual financial history

Up to three published annual periods. The chart shows financial statement amounts; missing observations are not connected. Each company chart uses its own scale; compare amounts in the table.

Chart metric

WST · Exact amounts and source periods · USD
Period end	Revenue	Filing date
December 2023	2,949,800,000.0000	Feb 17, 2026
December 2024	2,893,200,000.0000	Feb 17, 2026
December 2025	3,074,100,000.0000	Feb 17, 2026

Annual periods · USD

Period end	Revenue	Net income	Operating cash flow	Total assets	Total liabilities	Filing date
December 2025	3,074,100,000.0000	493,700,000.0000	754,800,000.0000	4,270,000,000.0000	1,094,000,000.0000	Feb 17, 2026
December 2024	2,893,200,000.0000	492,700,000.0000	653,400,000.0000	3,643,400,000.0000	961,100,000.0000	Feb 17, 2026
December 2023	2,949,800,000.0000	593,400,000.0000	776,500,000.0000	—	—	Feb 17, 2026

Financial inputs behind the calculation

Financial inputs	USD	Period end	Filing date	Form
RevenueRevenueFromContractWithCustomerExcludingAssessedTax	$3.07B	December 2025	Feb 17, 2026	10-K
Previous period revenueRevenueFromContractWithCustomerExcludingAssessedTax	$2.89B	December 2024	Feb 17, 2026	10-K
Net incomeNetIncomeLoss	$493.7M	December 2025	Feb 17, 2026	10-K
Operating cash flowNetCashProvidedByUsedInOperatingActivities	$754.8M	December 2025	Feb 17, 2026	10-K
Total assetsAssets	$4.27B	December 2025	Feb 17, 2026	10-K
Total liabilitiesLiabilities	$1.09B	December 2025	Feb 17, 2026	10-K

New filings

Explore methodology ↗